Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

US FDA identifies recall of Getinge's heart devices as most serious

Published 03/31/2023, 02:15 PM
Updated 03/31/2023, 04:16 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

(Reuters) - The U.S. health regulator on Friday classified the recall of Getinge AB's heart devices as its most serious type as their use may cause grave injuries or death due to risk of unexpected shutdowns.

The company said it has informed its customers about the issue and there was no material financial impact from the recall. 

An estimated 4,502 devices were recalled by the Swedish medical equipment maker's unit, Datascope, in the country in January, according to the U.S. Food and Drug Administration (FDA).

A communication loss between certain chips may result in an unexpected shutdown of the devices, which are designed to help the heart pump more blood, the agency said.

Unexpected pump shutdown and any interruption to therapy could lead to unstable blood flow, organ damage, including death, especially for critically ill people.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Datascope has reported 42 complaints about the communication failures resulting in unexpected shutdowns of the devices, distributed between March 6, 2012, and Jan. 13 of this year, the FDA said. It added there were no reports of any injuries or deaths related to the issue.

Earlier in March, the FDA had classified recall of an estimated 2,300 of these devices as most serious due to a different issue. Getinge had also recalled 4,454 units initiated back in December due to another issue.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.